

**POSTER PRESENTATION****Open Access**

# Efficacy and safety of therapy of chronic hepatitis B with telbivudine (LdT) in patients with HIV-infection without HAART

SP Tsarenko<sup>1</sup>, AV Kravchenko<sup>2</sup>, VG Kanestri<sup>2</sup>, SL Maximov<sup>1\*</sup>

From Tenth International Congress on Drug Therapy in HIV Infection  
Glasgow, UK. 7-11 November 2010

## Introduction

According to the European recommendations (version 5.2., November 2009) at patients with the HIV-infection and chronic hepatitis B (CHB), not receiving HAART, adefovir and LdT may be used as an alternative regime. In the Russian Federation adefovir is not registered and tenofovir was registered only in March 2010.

## Objective

To study efficacy and safety LdT at patients with HIV-infection and CHB (HIV/CHB).

## Methods

12 patients with HIV/CHB (men 10), middle age of 33,5 years, without HAART (CD4 + - 450-650 cells/mm<sup>3</sup>), since 2009 received LdT (600 mg QD). All patients had HBsAg, HBV DNA. 9 from 12 patients had HBeAg. Duration of treatment has made 3-12 months.

## Summary of results

At all patients had the positive result of therapy with LdT: 7 patients had disappearance of HBV DNA in 1-6 months; at 1 patient after 3 months of therapy observed disappearance of HBsAg and appearance anti-HBs and LdT has been cancelled. At 5 patients through 6-9 months of treatment is marked a decreasing of level of HBV DNA on 2-3 log IU/ml. At 4 from 9 patients with HBeAg observed seroconversion to anti-HBe. In absence HAART registered fluctuations of level of HIV RNA was not statistically significant. The adverse events of therapy with LdT have not been registered.

## Conclusions

Therapy of CHB with LdT at patients with HIV-infection was effective: at 58,3 % of patients had disappearance of HBV DNA, and at 4 from 9 patients with HBeAg observed seroconversion. Influence of therapy with LdT on dynamics of HIV RNA it wasn't revealed.

## Author details

<sup>1</sup>Moscow State University of Medicine & Dentistry, 4-15, 8-ya str/ Sokolinoy Gory, Moscow, Russian Federation. <sup>2</sup>Russian Federal AIDS Center, Moscow, Russian Federation.

Published: 8 November 2010

doi:10.1186/1758-2652-13-S4-P209

**Cite this article as:** Tsarenko et al.: Efficacy and safety of therapy of chronic hepatitis B with telbivudine (LdT) in patients with HIV-infection without HAART. *Journal of the International AIDS Society* 2010 **13**(Suppl 4):P209.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>Moscow State University of Medicine & Dentistry, 4-15, 8-ya str/ Sokolinoy Gory, Moscow, Russian Federation  
Full list of author information is available at the end of the article